Mnemosyne Pharmaceuticals Inc.
Selective NMDA modulators for neuropsychiatric disorders
This article was originally published in Start Up
Executive Summary
Less than half of patients with major depressive disorder respond to current therapies; that’s why clinical studies showing that the anesthetic medication ketamine benefitted MDD patients within hours made headlines, despite ketamine’s serious drawbacks. Mnemosyne Pharmaceuticals Inc. has identified a highly selective oral compound that hits the same target as ketamine but with less of the effects that can lead to abuse.